Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment [0.03%]
原发性硬化性胆管炎（上）：流行病学、病因和发病机制、临床特征及治疗措施
James H Tabibian,Ahmad H Ali,Keith D Lindor
James H Tabibian
Primary sclerosing cholangitis (PSC) is a chronic, idiopathic cholangiopathy that can progress to cirrhosis, end-stage liver disease, hepatobiliary cancer, and/or colorectal cancer. The course of PSC is often complicated by portal hypertens...
Shannon J Morales,Kartik Sampath,Timothy B Gardner
Shannon J Morales
Endoscopic retrograde cholangiopancreatography (ERCP) is a diagnostic and therapeutic procedure employed in the management of disorders of the biliary system. Post-ERCP pancreatitis (PEP) is the most common complication of ERCP and can lead...
Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients [0.03%]
慢性肾病和肾移植受者中的丙型肝炎病毒治疗
Melissa Corson,Ashley Moch,Sammy Saab
Melissa Corson
An important interplay exists between hepatitis C virus (HCV) infection and chronic kidney disease (CKD). HCV infection is associated with an increased risk of morbidity and mortality in patients coinfected with CKD, and patients with CKD h...
Gary R Lichtenstein
Gary R Lichtenstein
A Noninvasive Method to Assess Mucosal Healing in Patients* With Crohn's Disease [0.03%]
评估克罗恩病患者黏膜愈合的无创方法
William J Sandborn,Maria T Abreu,Marla C Dubinsky
William J Sandborn
Ongoing inflammation in the gastrointestinal tract and loss of the mucosal barrier are key components of Crohn's disease. Current treatment paradigms, including treat-to-target, are based on improvement of both clinical and endoscopic sympt...
Stephen B Hanauer
Stephen B Hanauer
A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC Special Reporting on:• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus In [0.03%]
美国肝病研究协会年会亮点：2017 AASLD 肝脏会议丙型肝炎病毒领域综述报告摘要选编 • 2017 年 10 月 20 日至 24 日，华盛顿特区 特别报导：• Glecaprevir/Pibrentasvir 治疗成人基因1-6型慢性丙型肝炎患者的疗效、安全性和药代动力学
Vivek Kaul
Vivek Kaul
Guy E Boeckxstaens
Guy E Boeckxstaens